Abstract
To the Editor: The article by Lemna et al. (Feb. 1 issue)1 furthers the evaluation of the ΔF508 mutation, which is associated with some cases of cystic fibrosis. Although its real effect may be to help in documenting the substantial clinical variation that can occur among persons who possess the same small genetic deletion, the finding has encouraged calls for general screening for cystic fibrosis. This is already offered to the public by unregulated for-profit laboratories supported by biotechnology companies, generally without professional genetic counseling. Their services have become available despite the cautions expressed by the American Society of…
Original language | English |
---|---|
Pages (from-to) | 62-63 |
Number of pages | 2 |
Journal | New England Journal of Medicine |
Volume | 323 |
Issue number | 1 |
DOIs | |
State | Published - 5 Jul 1990 |
Externally published | Yes |